Investors have backed a new precision medicine company targeting clonal hematopoiesis with $40 million. Tensixteen Bio Inc. is on a mission to understand how somatic mutations influence age-related diseases, including cancer. The San Francisco-based startup will use the funds to develop a genomics and clinical platform that can identify patients at high risk of developing disease.

Chinese neuroscientists have identified a bone marrow (BM) response to acute brain injury, in which the fate and function of BM hematopoietic cells are shaped by brain injury, suggesting that the brain can mobilize a population of protective monocytes and direct them to the injury site.